Introducing Salmogenics™: A Patented Vaccine to Combat Salmonella

1. (OTC Pink:GOGC)

2. Forward-Looking Statement This presentation contains statements that constitute “forward-looking” statements within the meaning of the Securities Act of 1993 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. “Forward-looking” statements contained in this presentation include the intent, belief or current expectations of the Company and its senior management team with respect to future actions by the Company, prospects of the Company’s operations, profits from future operations, overall future business prospects and long-term stockholder value, as well as the assumptions upon which such statements are based. Investors are cautioned that any such “forward-looking” statements are not guarantees of future performance, and that actual results may differ materially from those contemplated by such “forward-looking” statements. Important factors currently known to management that could cause actual results to differ materially from those contemplated by the “forward-looking” statement in this presentation include, but are not limited to, adverse developments involving operations of the Company’s business units, failure to meet operating objectives or to execute the business plan, the failure to reach revenue or profit projections and the failure to retain and hire key personnel and management. The Company undertakes no obligation to update or revise the “forward-looking” statements contained in this presentation to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

3. Corporate Description Global Green, Inc. introduces Salmogenics™, a new patented vaccine to help combat the dangerous effects that Salmonella bacteria produce in animals and human beings. Global Green, upon USDA approval, plans to manufacture, market and sell the vaccine in the poultry industry.

4. A unique, new patented vaccine to combat the devastating effects of Salmonella

5. Why This Vaccine? No Live Injection In-Ovo Injection Healthier Chicken

6. Company Highlights • Worldwide Market Opportunity • Exclusive Rights to Two Patents Owned by N.H.I.L., a research affiliate and majority shareholder • Only Source of New Patented Vaccine Offering: • Protection from deadly Salmonella bacteria • Healthier protein source • Potential to improve the lives of millions of people • Product Expansion Potential

7. Agenda • Market Opportunity • Business Strategy

8. Market Opportunity

9. Market Overview • Approximately 1.3 billion humans contract salmonella annually, with 2-3 million resulting in death • 1 million humans in the U.S. contract salmonella annually • 40 billion chickens will benefit from the salmonella vaccine • Salmonella is the scientific name for over 2,500 types of bacteria

11. The Problem is Public “Salmonella is common in poultry, so it’s not illegal for meat to be tainted with the pathogen.”CBS News, August 2011 “For every laboratory-confirmed case of Salmonella, there are at least 29 unreported cases.”Centers for Disease Control, 2011

14. 2010 USDA Mandate Reduce the percentage of Salmonella infected chicken allowed on the market from 7% to 5% Salmogenics has been shown in efficacy studies to help accomplish these strict requirements

15. USDA Approval Progress • In last stages of testing and trials • Vaccine proven to be safe, non-toxic and causes no harm to the animal • Studies to date conclude that Salmogenics reduces Salmonella contamination

16. USDA Final Phase Status • Identify and contract USDA-approved vaccine manufacturer • Assure requirements from the vaccine manufacturer will meet USDA requirements • Conclusion submitted to USDA must specify: • vaccine product can be safely and standardly commercially applied by the intended customers • claims are sustainable and reproducible when applied to larger populations of birds • vaccine can be used in other circumstances such as a combined treatment with other vaccines • Submit final results to USDA for approval

17. A proven solution to reducing the incidence and prevalence of Salmonella in poultry, which can cause food poisoning in humans Changes the approach to the control of the spread of an economically devastating disease

20. Organic Poultry Retail Market Sales $600 Million $161 Million Source: USDA

21. Source: Dolcera Analysis

22. Key Growth DriversPoultry Vaccine Market(Estimated to be $5.4 billion by 2015) • Growth of diseases in animals • Increasing public awareness • Technological advancements • Ability of vaccines to • Promote growth • Develop immunity against diseases • Lower animal mortality rate Source: Global Industry Analysts

23. Multiple poultry caretakers involved Variety of vaccination equipment used Re-use of containers = vaccine residues Defective vaccine distribution patterns Mixing vaccines for a complete day Incorrect dosage of vaccine or diluent End Result: Added human interactions + labor costs + stress on poultry Potential Problems with Water Borne or Spray Vaccinations with Chickens

24. Advantages of In Ovo Vaccinations • Earlier immunity • Uniform delivery • Fast delivery • Reduced stress • Reduced labor costs • Future products Egg Yolk Needle Shell Air Chamber

25. The Global Green Advantageis Significant • Earlier immunity • Uniform delivery • Fast delivery • Reduced stress • Reduced labor costs • Improved productivity • Future products

26. Benefits to the Entire System Poultry Growers • Fast delivery • Uniform delivery system • Reduced labor costs for inoculation Chicken • Less trauma • Earlier immunity from Salmonella Humans Healthier protein source Environment Environmentally friendly • Food Service Handlers • Reduced contamination • Healthier customers and families

28. Additional Market Applications

29. Salmogenics = Safer Egg Worldwide egg market = 1.3 trillion eggs per year

30. +

31. Business Strategy

32. Business Strategy • Complete final requirements for USDA approval • Receive final approval by USDA • Develop marketing and sales structure to effectively convert market to Salmogenics • Establish Salmogenics as standard in the industry • Innovate through internal new product development • Establish a leadership position in vaccine technology with Salmogenics as the foundation

33. Top 10 Broiler Chicken CompaniesRepresenting 73.7% of Chickens Processed Annually #1 Tyson Foods, Inc. #2 Pilgrim’s Pride Corp. #3 Perdue Farms, Inc. #4 Sanderson Farms, Inc. #5 Koch Foods, Inc. #6 Wayne Farms, LLC #7 Mountainaire Farms, Inc. #8 House of Raeford Farms, Inc. #9 Foster Farms, Inc. #10 Peco Foods, Inc. Source: Watt PoultryUSA Feb 2010

34. Global Green Evolution and Growth Trajectory Future Growth and profitability Present Intense focus on sales and marketing strategy is gaining traction Past Developed Salmogenics vaccine

35. Market Penetration Strategies • Strong and reliable regulatory approvals • Research data publications • Company and product name recognition • Advertising in leading publications • Animal production • Food safety • Strong and experienced technical staff working with poultry industry experts • Strong sales force focusing on top tier customers

36. Major Players in Veterinary Vaccine Market Source: Company Annual Reports

37. Salmogenics Competitive Advantages • Patent positions • Improved immune system of fowl = improved health and welfare of bird and humans • Healthier chickens = healthier protein source • Vaccine injected directly into egg = reduced time and labor costs • End result = success of Salmogenics

38. Timeline • 1986 – Dr. Sotomayor began research on animal health vaccines • 1995 – Technology brought to U.S. • 1997 – USDA approved validation study begins • 2008 – NHIL secures worldwide rights to Salmogenics • 2010 – Studies as required by USDA contracted to AHPharma • 2010 – NHIL grants Salmogenics rights to Global Green • Feb 2011 – USDA Phase 4 trials began • May 2011 – Receive patent on vaccine composition

39. Timeline (cont’d) • Aug 2011 – Receive patent on method and composition • Oct 2011 – SEC approves Form S-1 (IPO) • Nov 2011 – Phase 4 Salmonella challenge study completed • March 2012 – FINRA approval • March 2012 – Final report on Phase 4 Efficacy/Challenge study • April 2012 – DTC application filed • April/May - USDA-approved production facility to be chosen

40. The Management Team Name Function Dr. Mehran Ghazvini, DC,NMD Chairman, CEO and Treasurer Dr. Rene Reed, DC, NMD VP, Secretary and Director

41. Investment Highlights • Worldwide Market Opportunity • Proprietary Patent Positions • Focused on Contributing to Human Welfare through Technology in Vaccines and other Nutraceuticals • Well Positioned for the Future • American-Made